Literature DB >> 27523470

Visceral leishmaniasis in a rheumatoid arthritis patient receiving methotrexate.

Delia Reina1, Dacia Cerdà2, Elena Güell3, Joaquín Martínez Montauti3, Antonio Pineda4, Hèctor Corominas2.   

Abstract

Patients with rheumatoid arthritis (RA) treated with disease-modifying antirheumatic drugs are susceptible to severe infections such as leishmaniasis. As L. infantum is endemic in the Mediterranean region, it is necessary to rule this infectious process out in any RA patient presenting with fever and pancytopenia. An early diagnosis based on a high suspicion can prevent a fatal outcome.
Copyright © 2016 Elsevier España, S.L.U. and Sociedad Española de Reumatología y Colegio Mexicano de Reumatología. All rights reserved.

Entities:  

Keywords:  Artritis reumatoide; Kala-azar; Methotrexate; Metotrexato; Rheumatoid arthritis

Mesh:

Substances:

Year:  2016        PMID: 27523470     DOI: 10.1016/j.reuma.2016.07.005

Source DB:  PubMed          Journal:  Reumatol Clin        ISSN: 1699-258X


  2 in total

1.  Visceral Leishmaniasis in the Mediterranean area.

Authors:  Dèlia Reina; Hèctor Corominas
Journal:  Eur J Rheumatol       Date:  2017-11-02

2.  Effect of immunosuppressants on the parasite load developed in, and immune response to, visceral leishmaniasis: A comparative study in a mouse model.

Authors:  Lorena Bernardo; Jose Carlos Solana; Alba Romero-Kauss; Carmen Sánchez; Eugenia Carrillo; Javier Moreno
Journal:  PLoS Negl Trop Dis       Date:  2021-02-01
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.